Implementing a Contingency Management Program Addressing Methamphetamine Use For and With the People of Hawaii

Part of paid clinical trials in Honolulu, Hawaii.

Sponsor
Queen's Medical Center
Study ID
NCT06532370
Status
Recruiting
Apply to this trial

Conditions

  • Contingency Managment
  • Methamphetamine Use Disorder

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Contingency Managment — BEHAVIORAL
    If the sample be methamphetamine negative, participant will be positively reinforced and offered incentives. Participants immediately draw the reinforcement slip of paper to receive a prize from a selection kept on-site. Approximately, half of the slips offer written praise (e.g. "great job!"). The other half of slips are then divided between low value (e.g. food gift cards, bus passes), medium value (e.g. prepaid cell phone, clothing gift cards), and a few large value rewards (e.g. iPad, jewelry). Should the sample be positive for methamphetamine, no reinforcement and/or incentive to be provided. Participant will be encouraged to continue to participate in CM program and follow-up on the next CM date.

Study Details

The goal of this clinical trial is to use contingency management (CM) as an intervention tool to address methamphetamine use. The main objectives are to: * Gather effectiveness data on a pilot a CM program for participants in Hawaii who use methamphetamine following hospitalization due to traumatic injury * To assess participant perspectives on engaging with a CM program based at a Level 1 Trauma Center. Researches will assess both patient-reported and biologically-confirmed medium-term program effectiveness and conduct qualitative interviews with participants post-program. Participants will: * Visit a follow-up clinic up to three times per week to complete urinalysis following discharge from the trauma unit * Complete Treatment Effectiveness Assessments at 6 and 12-weeks * Engage in a qualitative interview at the end of the CM program

Key Dates

Start date
Oct 10, 2024
Status verified
Mar 2026
Primary completion
Dec 30, 2026
Completion
Dec 30, 2026

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Contingency Managment
    Participants are allowed to complete CM three times per week for the maximum of 12-weeks. At the six- and 12-week time points, participants will complete the Treatment Effectiveness Assessment (TEA) with study personnel.

Primary Outcome Measure

TEA Outcomes at 6 and 12-weeks [ Time Frame: From enrollment to 6 and 12-weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The Queen's Medical CenterHonoluluHawaii90813
Nicholas Schumann
[email protected]
8086917024

Find similar trials in Honolulu, HI

By research site
The Queen's Medical Center· Honolulu, HI

Related Studies